The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-κB-dependent mechanism of p53 suppression in tumors
Open accessAbstract
Renal cell carcinomas (RCC) commonly retain wild-type but functionally inactive p53, which is repressed by an unknown dominant mechanism. To help reveal this mechanism, we screened a diverse chemical library for small molecules capable of restoring p53-dependent transactivation in RCC cells carrying a p53-responsive reporter. Among the compounds isolated were derivatives of 9-aminoacridine (9AA), including the antimalaria drug quinacrine, which strongly induced p53 function in RCC and other types of cancer cells. Induction of p53 by these compounds does not involve genotoxic stress and is mediated by suppression of NF-κB activity. In contrast to agents that target IκB kinase 2, 9AA and quinacrine can effectively suppress both basal and inducible activities of NF-κB, representing inhibitors of a previously undescribed type that convert NF-κB from a transactivator into a transrepressor, leading to accumulation of inactive nuclear complexes with unphosphorylated Ser-536 in the p65/RelA subunit. p53 function in RCC can be restored by ectopic expression of a superrepressor of IκB as effectively as by 9AA-derived compounds. These findings suggest that the complete or partial repression of p53 observed in many tumors can be the result of constitutive activation of NF-κB. The results demonstrate, in principle, the possibility to kill cancer cells selectively through simultaneous inhibition of NF-κB and activation of p53 by a single small molecule and suggest anticancer applications for the well known antimalaria drug quinacrine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Phosphorylation of NF-κB and IκB proteins: implications in cancer and inflammation
Viatour, P., Merville, M.-P., Bours, V., & Chariot, A. (2005) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2004.11.009 · Cited by 1,496
The Phosphorylation Status of Nuclear NF-ΚB Determines Its Association with CBP/p300 or HDAC-1
Zhong, H., May, M. J., Jimi, E., & Ghosh, S. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00477-x · Cited by 939
IKKα limits macrophage NF-κB activation and contributes to the resolution of inflammation
Lawrence, T., Bebien, M., Liu, G. Y., Nizet, V., & Karin, M. (2005) · Nature · doi:10.1038/nature03491 · Cited by 626
Transcriptional Cross Talk between NF-κB and p53
Webster, G. A., & Perkins, N. D. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3485 · Cited by 598
Histone H3 phosphorylation by IKK-α is critical for cytokine-induced gene expression
Yamamoto, Y., Verma, U. N., Prajapati, S., Kwak, Y.-T., & Gaynor, R. B. (2003) · Nature · doi:10.1038/nature01576 · Cited by 577
NF-κB as a therapeutic target in cancer
Orlowski, R. Z., & Baldwin, A. S. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02375-4 · Cited by 553
The IKK/NF-κB activation pathway—a target for prevention and treatment of cancer
Greten, F. (2004) · Cancer Letters · doi:10.1016/j.canlet.2003.08.029 · Cited by 410
Kim, C.-S., Kawada, T., Kim, B.-S., Han, I.-S., Choe, S.-Y., Kurata, T., & Yu, R. (2003) · Cellular Signalling · doi:10.1016/s0898-6568(02)00086-4 · Cited by 328
TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer.
Olivier, M., Hussain, S. P., de Fromentel, C. C., Hainaut, P. L., & Harris, C. C. (2004) · PubMed · Cited by 243
Cahir-McFarland, E. D., Carter, K., Rosenwald, A., Giltnane, J. M., Henrickson, S. E., Staudt, L. M., & Kieff, E. (2004) · Journal of Virology · doi:10.1128/jvi.78.8.4108-4119.2004 · Cited by 233
IKKα, IKKβ, and NEMO/IKKγ Are Each Required for the NF-κB-mediated Inflammatory Response Program
Li, X., Massa, P. E., Hanidu, A., Peet, G. W., Aro, P., Savitt, A., Mische, S., Li, J., & Marcu, K. B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205165200 · Cited by 223
Critical Role for Lysines 21 and 22 in Signal-induced, Ubiquitin-mediated Proteolysis of IkB-α
Baldi, L., Brown, K., Franzoso, G., & Siebenlist, U. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.1.376 · Cited by 177
Characterization of an Amsacrine-resistant Line of Human Leukemia Cells
Zwelling, L. A., Hinds, M., Chan, D., Mayes, J., Sie, K. L., Parker, E., Silberman, L., Radcliffe, A., Beran, M., & Blick, M. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)84722-1 · Cited by 176
Constitutive activation of nuclear factor-κB prevents TRAIL-induced apoptosis in renal cancer cells
Oya, M., Ohtsubo, M., Takayanagi, A., Tachibana, M., Shimizu, N., & Murai, M. (2001) · Oncogene · doi:10.1038/sj.onc.1204525 · Cited by 164
Clinical update: proteasome inhibitors in solid tumors
LENZ, H. (2003) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00082-3 · Cited by 159
The use of quinacrine (Atabrine) in rheumatic diseases: A reexamination
Wallace, D. J. (1989) · Seminars in Arthritis and Rheumatism · doi:10.1016/0049-0172(89)90050-4 · Cited by 147
Inhibition of constitutive NF-κB activity by IκBαM suppresses tumorigenesis
Fujioka, S., Sclabas, G. M., Schmidt, C., Niu, J., Frederick, W., Dong, Q. G., Abbruzzese, J. L., Evans, D. B., Baker, C. H., & Chiao, P. J. (2003) · Oncogene · doi:10.1038/sj.onc.1206323 · Cited by 146
Increased nuclear factor-κB activation is related to the tumor development of renal cell carcinoma
Oya, M., Takayanagi, A., Horiguchi, A., Mizuno, R., Ohtsubo, M., Marumo, K., Shimizu, N., & Murai, M. (2003) · Carcinogenesis · doi:10.1093/carcin/24.3.377 · Cited by 123
p53 Pathway in Renal Cell Carcinoma Is Repressed by a Dominant Mechanism
Gurova, K. V., Hill, J. E., Razorenova, O. V., Chumakov, P. M., & Gudkov, A. V. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1541 · Cited by 119
Self-citationNuclear factor‐KappaB modulation as a therapeutic approach in hematologic malignancies
Panwalkar, A. W., Verstovšek, S., & Giles, F. J. (2004) · Cancer · doi:10.1002/cncr.20182 · Cited by 104
Müerköster, S. S., Arlt, A., Witt, M., Gehrz, A., Haye, S., March, C., Grohmann, F., Wegehenkel, K., Kalthoff, H., Fölsch, U. R., et al. (2003) · International Journal of Cancer · doi:10.1002/ijc.10963 · Cited by 94
NF-κB inhibits transcription of the H+-K+-ATPase α2-subunit gene: role of histone deacetylases
Zhang, W., & Kone, B. C. (2002) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00156.2002 · Cited by 73
Sohn, T. A., Bansal, R. K., Su, G. H., Murphy, K. M., & Kern, S. E. (2002) · Carcinogenesis · doi:10.1093/carcin/23.6.949 · Cited by 49
Neznanov, N., Neznanova, L., Kondratov, R. V., Burdelya, L., Kandel, E., O’Rourke, D. M., Ullrich, A., & Gudkov, A. V. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210698200 · Cited by 33
Self-citationSetting the stage for transformation: HTLV-1 Tax inhibition of p53 function
Cynthia, A. P.-M. (2005) · Frontiers in bioscience · doi:10.2741/1586 · Cited by 32
Loss of Nuclear Factor-κB Is Tumor Promoting but Does Not Substitute for Loss of p53
Ryan, K. M., O’Prey, J., & Vousden, K. H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1474 · Cited by 31
Cellular senescence and cancer
(1999) · doi:10.1002/(sici)1096-9896(199901)187:1
Cited by
Awakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881
p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload
Sano, M., Minamino, T., Toko, H., Miyauchi, H., Orimo, M., Qin, Y., Akazawa, H., Tateno, K., Kayama, Y., Harada, M., et al. (2007) · Nature · doi:10.1038/nature05602 · Cited by 905
Inhibiting NF-κB activation by small molecules as a therapeutic strategy
Gupta, S. C., Sundaram, C., Reuter, S., & Aggarwal, B. B. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2010.05.004 · Cited by 762
An Agonist of Toll-Like Receptor 5 Has Radioprotective Activity in Mouse and Primate Models
Burdelya, L. G., Krivokrysenko, V. I., Tallant, T. C., Strom, E., Gleiberman, A. S., Gupta, D., Kurnasov, O. V., Fort, F. L., Osterman, A. L., DiDonato, J. A., et al. (2008) · Science · doi:10.1126/science.1154986 · Cited by 705
Self-citationp53 signaling in cancer progression and therapy
Marei, H. E., Althani, A., Afifi, N., Hasan, A., Caceci, T., Pozzoli, G., Morrione, A., Giordano, A., & Cenciarelli, C. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02396-8 · Cited by 588
Metadata
- Authors
- Gurova, K. V., Hill, J. E., Guo, C., Prokvolit, A., Burdelya, L. G., Samoylova, E., Khodyakova, A. V., Ganapathi, R., Ganapathi, M., Tararova, N. D., Bosykh, D., Lvovskiy, D., Webb, T. R., Stark, G. R., & Gudkov, A. V.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2005-11-15
- Volume
- 102
- Issue
- 48
- Pages
- 17448-17453
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2031019010
- Cited by
- 265
- References
- 28
- FWCI
- 4.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.